E7.8

Deprescribing in the Encounter

Stopping medications is a clinical act that requires the same care as starting them. Do it deliberately, slowly, with the patient.

Encounter card

Setting

When a medication no longer serves the patient, was added inappropriately, has caused side effects exceeding benefit, or the patient wants to discontinue.

Opening move

Identify the candidate for deprescribing. Discuss with the patient — what the medication was for, what discontinuation involves, how to monitor for relapse or withdrawal. Taper slowly. Reassess.

Sample language

"You've been on benzodiazepines for 3 years. They've served their purpose, and now I'm worried about long-term harm. Let's plan to taper slowly."
"We added quetiapine for sleep 2 years ago. You're doing well. Let's think about whether we still need it."
"Tapering is slow on purpose — over months, not weeks. We'll watch for any signs of return of symptoms or withdrawal."

Listen for

Patient's feelings about discontinuing (often anxiety even when intellectually agreeing). Specific concerns about relapse. Hidden reasons for staying on a medication (e.g., as a security object).

Common pitfalls

Stopping too quickly. Stopping multiple medications simultaneously. Not building in monitoring. Discontinuing without addressing what the medication was doing for the patient.

Red flags / escalate: Acute symptom recurrence during taper — pause and reassess. Withdrawal symptoms (especially with benzodiazepines, paroxetine, venlafaxine). Patient catastrophizing every minor symptom as relapse.

Documentation

Drug, prior dose, taper schedule, monitoring plan, patient agreement.

Real-world reality: Deprescribing takes more time than prescribing. The benzodiazepine taper conversation, with monitoring across months, is unbilled clinical work that prevents the alternative scenario where the medication continues indefinitely.

Deprescribing is clinical work. The same effort that goes into prescribing should go into stopping.

Warm grey-tinted clinical notebook page, muted teal accent. Deliberate deprescribing — identify candidate, discuss with patient, taper slowly, reassess. Margin clusters on each step.

Deprescribing — stopping medications that are no longer serving the patient — is clinical work that deserves the same care as starting medications. Done well, it reduces side effect burden, simplifies regimens, and often improves function. Done poorly, it triggers withdrawal, missed symptoms, or premature discontinuation that undoes the original treatment.

Identify candidates for deprescribing at every visit with patients on long-term medication. The benzodiazepine that was started for acute anxiety three years ago and continues from inertia. The antipsychotic added during a hospitalization that may no longer be needed. The PRN sleep aid that's now nightly. The combination that's accumulated without anyone systematically reviewing whether each component is still earning its place. Periodic medication review identifying deprescribing candidates is part of good care.

Discuss with the patient. Don't deprescribe without explaining. "You've been on this for three years; let's think about whether we still need it." Patients often have feelings about deprescribing — fear that symptoms will return, attachment to the medication as security, sometimes relief that you're suggesting it. Address the feelings as you plan the taper.

Taper slowly, calibrated to the drug. Benzodiazepines often require taper over months. SSRIs over weeks. Antipsychotics often over weeks to months. The faster the taper, the more likely the patient will experience withdrawal symptoms that they (and you) may misinterpret as recurrence of the original condition. Slow tapers tolerate better and produce cleaner clinical pictures.

Distinguish withdrawal from relapse. Withdrawal typically emerges quickly (days), follows a stereotyped pattern related to the drug's pharmacology, and resolves with re-dosing or completion of the withdrawal window. Relapse takes longer to emerge (weeks), looks like the original condition, and doesn't resolve with brief re-dosing. The patient who has flu-like symptoms and dizziness within 48 hours of stopping venlafaxine is in withdrawal; the patient whose depression returns four weeks after stopping is in relapse.

Reassess at intervals. Deprescribing isn't always successful; sometimes symptoms re-emerge and the medication should be restarted. That's a clinical outcome, not a failure. Resume what was working; document the trial.

Sample taper schedules for different medications — BZDs (months), SSRIs (weeks), antipsychotics (weeks to months). Margin notes on each.

The anchor

Deprescribing is clinical work. Identify candidate, discuss with patient, taper slowly, monitor for withdrawal vs relapse, reassess.

Withdrawal symptoms vs return of original condition — different time course, different symptom pattern. Margin clusters on the distinction.

Prove it

A patient on alprazolam 1mg TID for 8 years wants to discontinue. How do you plan the taper?

This connects to

R11.8

Polypharmacy & Rational Combinations (V3)

The pharmacology context.

R6.2

Alprazolam (V3)

The specific drug context.

Locked concepts unlock as you reach them on the path.